Artisan Partners released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”, focusing on companies with franchise characteristics and strong earnings trajectories. US equities ended the year with robust fourth-quarter gains. The Fund’s top five holdings offer insights into key selections for 2025. Argenx SE (NASDAQ:ARGX) was a top contributor to the Fund’s performance, with a stock price of $826.25 per share on February 23, 2026, and a market capitalization of $51.131 billion.

In the fourth quarter 2025 investor letter, Artisan Mid Cap Fund highlighted the performance of Argenx SE (NASDAQ:ARGX), a commercial-stage biopharma company. Argenx SE (NASDAQ:ARGX) stock closed at $826.25 per share on February 23, 2026, with a one-month return of -0.83% and a 31.96% gain over the past 52 weeks. The company has a market capitalization of $51.131 billion.

Argenx SE (NASDAQ:ARGX) was a top contributor to the Fund’s performance in the fourth quarter, with its first-in-class auto-immune therapy VYVGART® showing strong sales growth. The stock pulled back after discontinuing a mid-stage trial for thyroid eye disease but offers potential for additional indications. The company’s annualized sales for VYVGART® exceeded $4 billion.

Argenx SE (NASDAQ:ARGX) is not among the 30 most popular stocks among hedge funds, with 47 hedge fund portfolios holding the stock at the end of the fourth quarter. While acknowledging its investment potential, certain AI stocks are seen as offering greater upside potential with less downside risk. Consider exploring free reports on the best short-term AI stocks for investment opportunities.

Read more at Yahoo Finance: Artisan Mid Cap Fund Maintains Its Confidence in Argenx’s (ARGX) VYVGART